Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: A prospective randomized double-blinded multicentre trial

Journal of Viral Hepatitis

Volumn 21, Issue 10, 2014, Pages 744-750

  Wiegand, J ^a   Wedemeyer, H ^b   Franke, A ^c   Rossler S ^d   Zeuzem, S ^e   Teuber, G ^f   Wachtler M ^g   Rommele U ^h   Ruf, B ⁱ   Spengler, U ^j   Trautwein, C ^k   Bock, C T ^l   Fiedler, G M ^a   Thiery, J ^a   Manns, M P ^b   Brosteanu, O ^c   Tillmann, H L ^a,m  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d KLINIKUM CHEMNITZ   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f Private Practice   (Germany)

^g Klinikum Schwabing   (Germany)

^h Klinikum Kirchheim Nürtingen   (Germany)

ⁱ Klinikum St Georg   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^l ROBERT KOCH INSTITUTE   (Germany)

^m DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

acute liver failure; entecavir; fulminant hepatitis B; telbivudine; tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FULMINANT HEPATIC FAILURE; GASTROENTERITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MORBIDITY; MULTICENTER STUDY; NONHUMAN; PROSPECTIVE STUDY; PROTHROMBIN TIME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BILIRUBIN; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908212992     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12210     Document Type: Article

References (25)

1. Tillmann HL, Zachou K, Dalekos GN,. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int 2012; 32: 544-553.
2. Cornberg M, Protzer U, Petersen J, et al,. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection-the German guideline]. Z Gastroenterol 2011; 49: 871-930.
3. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
4. Robert Koch Institut. Virus hepatitis B, C und D im Jahr 2011. Epid Bull 2012; 38: 371-388.
5. Sako A, Yasunaga H, Horiguchi H, et al,. Acute hepatitis B in Japan: incidence, clinical practices and health policy. Hepatol Res 2011; 41: 39-45.
6. Arteaga-Rodriguez A, Carrasco-Garrido P, de Lopez AA, et al,. Trends of acute hepatitis B hospitalizations, comorbidities, fatality rate, and costs associated with the hospitalization in Spain (2001-2006). Eur J Gastroenterol Hepatol 2010; 22: 961-966.
7. Tillmann HL, Hadem J, Leifeld L, et al,. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263.
8. Yu JW, Sun LJ, Zhao YH, et al,. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-783.
9. Yu JW, Sun LJ, Yan BZ, et al,. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499-506.
10. Torii N, Hasegawa K, Ogawa M, et al,. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002; 24: 34.
11. Kondili LA, Osman H, Mutimer D,. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11: 427-431.
12. Lisotti A, Azzaroli F, Buonfiglioli F, et al,. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008; 5: 309-312.
13. Chalupa P, Holub M,. Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy. Clin Infect Dis 2009; 49: 481.
14. Kumar M, Satapathy S, Monga R, et al,. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.
15. Schomerus H, Wiedmann KH, Dolle W, et al,. (+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology 1984; 4: 331-335.
16. Galsky J, Bansky G, Holubova T, et al,. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999; 28: 249-253.
17. Gunduz H, Karabay O, Tamer A, et al,. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol 2003; 9: 2698-2700.
18. Narendranathan M, Remla A, Mini PC, et al,. A trial of Phyllanthus amarus in acute viral hepatitis. Trop Gastroenterol 1999; 20: 164-166.
19. Galli M, Crocchiolo P, Negri C, et al,. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res 1985; 11: 665-669.
20. Jaeckel E, Cornberg M, Wedemeyer H, et al,. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
21. Wiegand J, Buggisch P, Boecher W, et al,. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-256.
22. Deterding K, Gruner N, Buggisch P, et al,. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13: 497-506.
23. Manns MP, Meyer S, Wedemeyer H,. The german network of excellence for viral hepatitis (hep-net). Hepatology 2003; 38: 543-544.
24. Schmilovitz-Weiss H, Ben Ari Z, Sikuler E, et al,. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004; 24: 547-551.
25. Xie F, Yan L, Lu J, et al,. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One 2013; 8: e54773.